NCT07151209View on ClinicalTrials.gov

Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Iparomlimab and Tuvonralimab combined with lenvatinib and SOX

Iparomlimab and Tuvonralimab:5 mg/kg Q3W lenvatinib:8 mg/day orally SOX：oxaliplatin (130 mg/m² Q3W intravenous infusion), and S-1 (40 mg/m² BID orally on days 1-14)

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER